-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 MCb4ETrBS85kkk1hXX6Lyn3tDgD24/mwVYWA2JP6Hg5s3pwsAHqZKaBU/IWx+Esi
 sje20/NxxlPgskeYXJWYpA==

<SEC-DOCUMENT>0001156973-06-001424.txt : 20080305
<SEC-HEADER>0001156973-06-001424.hdr.sgml : 20080305
<ACCEPTANCE-DATETIME>20061222060114
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001156973-06-001424
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20061222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KONINKLIJKE PHILIPS ELECTRONICS NV
		CENTRAL INDEX KEY:			0000313216
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTRONIC & OTHER ELECTRICAL EQUIPMENT (NO COMPUTER EQUIP) [3600]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		BREITNER CENTER
		STREET 2:		AMSTELPLEIN 2
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1096 BC
		BUSINESS PHONE:		31 20 59 77777

	MAIL ADDRESS:	
		STREET 1:		BREITNER CENTER
		STREET 2:		AMSTELPLEIN 2
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1096 BC

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPS ELECTRONICS N V
		DATE OF NAME CHANGE:	19930727

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPS NV
		DATE OF NAME CHANGE:	19910903
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
<TITLE>corresp</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>LETTERHEAD KONINKLIJKE PHILIPS ELECTRONICS N.V.</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>PHILIPS
HAS CLAIMED CONFIDENTIAL TREATMENT OF PORTIONS OF<BR>THIS LETTER IN ACCORDANCE WITH 17 C.F.R.
&#167; 200.83</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">December&nbsp;21, 2006
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Cecilia D.
Blye<BR>
Chief<BR>
Office of Global Security Risk<BR>
Securities and Exchange Commission<BR>
100 F Street, N.E.<BR>
Washington, D.C. 20549<BR>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>RE: Koninklijke Philips Electronics N.V. &#150; Form 20-F for the
Fiscal Year Ended December&nbsp;31, 2005 (File No.&nbsp;001-05146-01)</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dear Ms.&nbsp;Blye:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Thank you for your letter dated November&nbsp;16, 2006 setting forth requests for supplemental
information relating to the Form 20-F for the fiscal year ended December&nbsp;31, 2005 (the &#147;2005 Form
20-F&#148;) of Koninklijke Philips Electronics N.V. (&#147;Philips&#148; or the &#147;Company&#148;), filed with the
Commission on February&nbsp;13, 2006, and to our Response Letter dated October&nbsp;19, 2006 submitted in
response to your letter dated March&nbsp;16, 2006.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Philips&#146; responses to your comments are set forth below. To facilitate your review, we have
included in this letter the captions and numbered comments from your comment letter in italicized
text, and have provided Philips&#146; responses immediately following each numbered comment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company acknowledges that (i)&nbsp;the Company is responsible for the adequacy and accuracy of the
disclosure in the filing, (ii)&nbsp;Staff comments or changes to disclose in response to Staff comments
in the Reports reviewed by the Staff do not foreclose the Commission from taking any action with
respect to the filing, and (iii)&nbsp;the Company may not assert Staff comments as a defense in any
proceeding initiated by the Commission or any person under the federal securities laws of the
United States.
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>General</U>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><I>1.</I></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><I>We note your reference to U.S. policies approving sales of medical products and the statement
that such sales should not carry the reputational risk of other products, &#147;such as dual use items
or other products that are barred by either the OFAC sanctions or the EAR&#148;. Please note that
medical products may incorporate technology that presents dual-use concerns. Please expand your
description of the nature of your product sales, including but not limited to medical product
sales, to address whether, to the best of your knowledge and belief, any of your products sold into
the referenced countries incorporate any dual-use items or technology. If, to the best of your
knowledge and belief, none of your products sold in connection with your operations described in
your October&nbsp;19 letter include dual-use items or technology, please so state. To the extent your
response identifies dual-use items or technology, please also expand your qualitative materiality
analysis to address such sales.</I></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Response:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">It is OFAC and BIS policy to require medical equipment to be classified as EAR99 as a prerequisite
to issuing export licenses under TSRA. Some of the medical equipment that Philips Medical Systems
sells into the referenced countries incorporates dual-use components, but under the terms of EAR
770.2(b)(1), the individual component parts that are physically incorporated into the machine or
equipment do not require a license. The license or general exception under which the complete
machine or unit of equipment is exported will also cover its component parts, provided that the
parts are normal and usual components of the machine or equipment being exported, or that the
physical incorporation is not used as a device to evade the requirement for a license.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Our medical equipment is classified as EAR99 according to the Export Administration Regulations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We also take care in servicing of medical equipment either to comply with the strict one-for-one
replacement requirements of License Exception RPL, set forth in EAR 740.10 and 746.2(a)(1)(v) and
31 C.F.R. 515.533(a)(1), or to obtain the required licenses to supply replacement items. Such
licenses have conditions intended to ensure that dual-use components are only used as components in
the medical equipment and are not diverted to other applications. This way of treating service
components comports with long established U.S. Government policy for such components.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Given that all dual-use items are incorporated into medical equipment that is sold under a Commerce
Department license or an exception to Commerce&#146;s licensing regulations, Philips does not believe
that these sales would likely adversely affect its reputation or would otherwise be material from a
qualitative standpoint.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">As stated in our October&nbsp;19 letter, the other divisions of Philips did not ship dual-use items to
Cuba, Iran, or Syria during the period 2003, 2004, 2005.
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
</DIV>
<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><I>2.</I></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><I>Please confirm that your qualitative materiality analysis takes into account the broadened Iran
sanctions adopted in the Iran Freedom Support Act signed in September&nbsp;2006, or expand your analysis
to address the effect, if any, that you believe the broadened sanctions may have on your sales to
and contacts with Iran.</I></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Response:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We have reviewed the broadened sanctions contained in the Iran Freedom Support Act carefully and
have concluded that they will not have any additional effect on our sales to and contacts with
Iran. Given our product portfolio in Lighting, Consumer Electronics, Domestic Appliances and
Personal care and Medical Systems, Philips does <U>not</U> provide goods, services, technology, or
other items that would contribute materially to helping Iran acquire or develop chemical,
biological or nuclear weapons or related technologies or destabilizing numbers and types of
advanced conventional weapons. We also do <U>not</U> invest in Iran&#146;s petroleum, petroleum
by-product, and natural gas industries. As noted in our October&nbsp;19 letter, the Semiconductors
product division did not sell any products or services in or into, or derive revenues from, Cuba,
Iran and Syria during the years 2003, 2004 and 2005.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><I>3.</I></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><I>We note the statement that you have several local distributors in Iran and Syria. Please tell
us, to the best of your knowledge and belief, whether the governments of these countries or
entities controlled by them receive financing or act as intermediaries in connection with your
sales into or contacts with such countries.</I></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Response:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">To the best of our knowledge and belief, neither the governments of Iran or Syria nor entities
controlled by either of these governments receive financing or act as intermediaries in connection
with our sales into or contacts with these countries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Certain of our sales in these countries are made through agents and distributors to governmental
ministries of health. The sales in such cases are pre-approved through the export license protocol.
Financing is managed by those governmental entities and not by Philips. As indicated in our
response of October&nbsp;19, 2006, Philips&#146; sales in Iran and Syria are not significant.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><I>4.</I></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><I>We note your description of product sales into Venezuela purchased through Cimex Corporation of
Cuba. Please tell us whether, to the best of your knowledge and belief, any of the products that
you deliver to Venezuela are later sold or delivered to Cuba. To the extent you know or believe
that your medical products are indirectly sold to Cuba through Venezuela, please expand your
quantitative and qualitative materiality analysis to address such contacts.</I></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Response:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the time of export to Venezuela, our understanding was that all items were to be used in
Venezuela by the Ministry of Health.
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>&#091;CONFIDENTIAL INFORMATION IN RESPONSE TO THIS COMMENT HAS BEEN OMITTED AND FURNISHED SEPARATELY TO
THE SECURITIES AND EXCHANGE COMMISSION&#093;</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">* * *
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Please direct any questions or comments regarding the enclosed material to the undersigned at (011)
(31)&nbsp;20 59 77 241. Our fax number is (011) (31)&nbsp;20 59 77 150. We are available to discuss any of
the foregoing with you at your convenience.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Very truly yours,<BR>
<BR>
<BR>
&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">/s/ E.P. Coutinho<BR>
General Secretary and Chief Legal Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">cc: James Lopez<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Securities and Exchange Commission)<BR>
&nbsp;<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gerard Ruizendaal<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Wolter Boerman<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Albert Verdam<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Koninklijke Philips Electronics N.V.)<BR>
&nbsp;<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Andrew D. Soussloff<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;John O&#146;Connor<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Sullivan &#038; Cromwell LLP)

</DIV>








</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
